BR9811462A - Moléculas de tnfalfa modificadas, dna que codifica tais moléculas de tnfalfa modificadas e vacinas que compreendem tais tnfalfa modificadas e dna. - Google Patents
Moléculas de tnfalfa modificadas, dna que codifica tais moléculas de tnfalfa modificadas e vacinas que compreendem tais tnfalfa modificadas e dna.Info
- Publication number
- BR9811462A BR9811462A BR9811462-0A BR9811462A BR9811462A BR 9811462 A BR9811462 A BR 9811462A BR 9811462 A BR9811462 A BR 9811462A BR 9811462 A BR9811462 A BR 9811462A
- Authority
- BR
- Brazil
- Prior art keywords
- modified
- tnfalpha
- human
- molecules
- molecule
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 4
- 102000057041 human TNF Human genes 0.000 abstract 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/144—Tumor necrosis factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK41897 | 1997-04-15 | ||
| US4418797P | 1997-04-24 | 1997-04-24 | |
| PCT/DK1998/000157 WO1998046642A1 (en) | 1997-04-15 | 1998-04-15 | MODIFIED TNFα MOLECULES, DNA ENCODING SUCH MODIFIED TNFα MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFα MOLECULES AND DNA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9811462A true BR9811462A (pt) | 2000-09-12 |
Family
ID=8093298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9811462-0A BR9811462A (pt) | 1997-04-15 | 1998-04-15 | Moléculas de tnfalfa modificadas, dna que codifica tais moléculas de tnfalfa modificadas e vacinas que compreendem tais tnfalfa modificadas e dna. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7118750B1 (enExample) |
| EP (1) | EP0975668B1 (enExample) |
| JP (1) | JP2001521386A (enExample) |
| KR (1) | KR100522289B1 (enExample) |
| CN (1) | CN1178955C (enExample) |
| AR (1) | AR012427A1 (enExample) |
| AT (1) | ATE326481T1 (enExample) |
| AU (1) | AU743400B2 (enExample) |
| BR (1) | BR9811462A (enExample) |
| CA (1) | CA2289476A1 (enExample) |
| CZ (1) | CZ9903657A3 (enExample) |
| DE (1) | DE69834556T2 (enExample) |
| DK (1) | DK0975668T3 (enExample) |
| EE (1) | EE9900461A (enExample) |
| ES (1) | ES2264569T3 (enExample) |
| HR (1) | HRP980203B1 (enExample) |
| HU (1) | HUP0001930A3 (enExample) |
| IL (1) | IL132281A0 (enExample) |
| NO (1) | NO995002L (enExample) |
| NZ (1) | NZ337955A (enExample) |
| PL (1) | PL194221B1 (enExample) |
| RU (1) | RU2241715C2 (enExample) |
| SI (1) | SI0975668T1 (enExample) |
| SK (1) | SK285639B6 (enExample) |
| TR (1) | TR199902562T2 (enExample) |
| TW (1) | TW510921B (enExample) |
| UA (1) | UA72440C2 (enExample) |
| WO (1) | WO1998046642A1 (enExample) |
| ZA (1) | ZA983148B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| PT1159003E (pt) * | 1999-03-02 | 2011-02-22 | Centocor Inc | Anti-tnf alfa na terapêutica da asma resistente a esteróides |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| WO2000067777A1 (en) * | 1999-05-07 | 2000-11-16 | Biofan Pty Ltd | A method of prophylaxis and treatment and agents useful therefor |
| EE200200025A (et) | 1999-07-20 | 2003-04-15 | Pharmexa A/S | Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto |
| AU2001265830A1 (en) * | 2000-06-21 | 2002-01-02 | Ferring, B.V. | Solubilised protein vaccines |
| AU2003208314A1 (en) * | 2002-03-11 | 2003-09-22 | Pharmexa A/S | Novel application of vaccination against tnf-alpha |
| FR2844514B1 (fr) * | 2002-09-16 | 2007-10-19 | Neovacs | Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| KR20050118669A (ko) * | 2003-02-01 | 2005-12-19 | 뉴랄랩 리미티드 | 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화 |
| WO2005084198A2 (en) | 2004-02-27 | 2005-09-15 | Vaxconsulting | Peptides of il1 beta and tnf alpha and method of treatment using same |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| JP5757495B2 (ja) | 2005-05-16 | 2015-07-29 | アッヴィ バイオテクノロジー リミテッド | びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用 |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| KR20100084623A (ko) * | 2007-09-25 | 2010-07-27 | 인터벳 인터내셔널 비.브이. | 골관절염 치료용 백신 |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| CA2780130A1 (en) | 2009-11-05 | 2011-05-12 | The Uab Research Foundation | Treating basal-like genotype cancers |
| US8703712B2 (en) | 2010-03-18 | 2014-04-22 | The Uab Research Foundation | Targeting cancer stem cells with DR5 agonists |
| US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP2648746A1 (en) | 2010-12-08 | 2013-10-16 | Neovacs | Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof |
| EP2462950A1 (en) | 2010-12-08 | 2012-06-13 | Neovacs | Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof |
| CN102539778A (zh) * | 2010-12-24 | 2012-07-04 | 北京义翘神州生物技术有限公司 | 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒 |
| JP2011201902A (ja) * | 2011-05-19 | 2011-10-13 | Wyeth Llc | 可溶性Ａ−βに対する抗体を生成させるための能動免疫 |
| CN103376327A (zh) * | 2012-04-28 | 2013-10-30 | 通用电气公司 | 检测抗体或融合蛋白的浓度的方法 |
| WO2016179430A1 (en) | 2015-05-05 | 2016-11-10 | Rubicon Biotechnology Llc | Cancer immunotherapeutic |
| CN106279403B (zh) * | 2016-08-16 | 2019-06-11 | 长春市海兰深生物医学技术有限公司 | 一种检测天然肺癌相关抗体的组合物、试剂盒和方法 |
| CN106478802B (zh) * | 2016-10-11 | 2019-08-09 | 浙江省人民医院 | TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0251037B1 (en) * | 1986-06-20 | 1994-06-15 | Dainippon Pharmaceutical Co., Ltd. | Novel human TNF polypeptide mutants and DNAs encoding said mutants |
| DE3843534A1 (de) * | 1988-12-23 | 1990-07-12 | Basf Ag | Neue tnf-polypeptide |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| AU634379B2 (en) | 1991-04-29 | 1993-02-18 | Csl Limited | Recombinant immunocastration vaccine |
| SE9102808L (sv) * | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
| DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
-
1998
- 1998-04-15 NZ NZ337955A patent/NZ337955A/xx unknown
- 1998-04-15 TR TR1999/02562T patent/TR199902562T2/xx unknown
- 1998-04-15 BR BR9811462-0A patent/BR9811462A/pt not_active Application Discontinuation
- 1998-04-15 PL PL98336295A patent/PL194221B1/pl not_active IP Right Cessation
- 1998-04-15 HR HR980203A patent/HRP980203B1/xx not_active IP Right Cessation
- 1998-04-15 JP JP54338798A patent/JP2001521386A/ja active Pending
- 1998-04-15 CZ CZ19993657A patent/CZ9903657A3/cs unknown
- 1998-04-15 WO PCT/DK1998/000157 patent/WO1998046642A1/en not_active Ceased
- 1998-04-15 UA UA99116210A patent/UA72440C2/uk unknown
- 1998-04-15 CN CNB988042142A patent/CN1178955C/zh not_active Expired - Fee Related
- 1998-04-15 AU AU70303/98A patent/AU743400B2/en not_active Ceased
- 1998-04-15 EP EP98916866A patent/EP0975668B1/en not_active Expired - Lifetime
- 1998-04-15 RU RU99122686/13A patent/RU2241715C2/ru not_active IP Right Cessation
- 1998-04-15 DE DE69834556T patent/DE69834556T2/de not_active Expired - Fee Related
- 1998-04-15 ES ES98916866T patent/ES2264569T3/es not_active Expired - Lifetime
- 1998-04-15 AR ARP980101722A patent/AR012427A1/es unknown
- 1998-04-15 CA CA002289476A patent/CA2289476A1/en not_active Abandoned
- 1998-04-15 SK SK1409-99A patent/SK285639B6/sk unknown
- 1998-04-15 SI SI9830845T patent/SI0975668T1/sl unknown
- 1998-04-15 ZA ZA9803148A patent/ZA983148B/xx unknown
- 1998-04-15 EE EEP199900461A patent/EE9900461A/xx unknown
- 1998-04-15 US US09/060,294 patent/US7118750B1/en not_active Expired - Fee Related
- 1998-04-15 AT AT98916866T patent/ATE326481T1/de not_active IP Right Cessation
- 1998-04-15 IL IL13228198A patent/IL132281A0/xx unknown
- 1998-04-15 DK DK98916866T patent/DK0975668T3/da active
- 1998-04-15 KR KR10-1999-7009504A patent/KR100522289B1/ko not_active Expired - Fee Related
- 1998-04-15 HU HU0001930A patent/HUP0001930A3/hu unknown
- 1998-07-20 TW TW087111808A patent/TW510921B/zh not_active IP Right Cessation
-
1999
- 1999-10-14 NO NO995002A patent/NO995002L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR012427A1 (es) | Moleculas de ftn-alfa modificadas, adn codificada y vacunas que comprenden dicha modificacion ftn-alfa y adn | |
| Goytisolo et al. | Identification of two DNA‐binding sites on the globular domain of histone H5. | |
| Zhang et al. | Circulating mitochondrial DAMPs cause inflammatory responses to injury | |
| Murthy et al. | Identification of conserved domains in Salmonella muenchen flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in vitro | |
| CN104470943B (zh) | 新肽及其用途 | |
| ES2265689T3 (es) | Composiciones terapeuticas para el tratamiento de la hipersecrecion mucosa. | |
| BRPI9710372B8 (pt) | composto, e, composição farmacêutica. | |
| ES2312179T3 (es) | Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1. | |
| ES2733220T3 (es) | Proteína de fusión de hGH-XTEN y su uso en el tratamiento de la deficiencia de la hormona del crecimiento | |
| BR9914643A (pt) | Vetores adeno-associados para expressão dofator viii por células alvo | |
| DE68926971D1 (de) | Klonierte gene, die für elam-1 und für dessen fusionsproteine kodieren sowie die exprimierten proteinprodukte, pharmazeutische zusammensetzungen und deren verwendung | |
| BRPI0417342A (pt) | fator estimulante de colÈnia de granulócitos glicopeguilado | |
| HRP20041108B1 (hr) | Peptidi povezani sa tumorom koji se vežu na mhc molekule | |
| MXPA06010205A (es) | Metodo y composiciones para el tratamiento de trastornos gastrointestinales. | |
| BRPI0411321A (pt) | vetor viral associado a adenovìrus, composição farmacêutica e método para tratar doença de alzheimer, e, uso do vetor viral associado a adenovìrus | |
| CN106170298B (zh) | 用于提高抗体稳定性的缓冲液制剂 | |
| BRPI0812795B8 (pt) | domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso de um domínio ou antagonista de tnfr1, ácido nucleico recombinante, vetor, célula hospedeira, e, composição farmacêutica | |
| EP4233888A2 (en) | Modified protein | |
| BR9911349A (pt) | Genes para a biossìntese de epotilonas | |
| CA2406233A1 (en) | Compositions for drug delivery | |
| BRPI0411510A (pt) | proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno | |
| WO2004031352A2 (en) | Interferon variants with improved properties | |
| Seo et al. | PEGylation improves the therapeutic potential of dimerized translationally controlled tumor protein blocking peptide in ovalbumin-induced mouse model of airway inflammation | |
| Wei et al. | Laggera alata attenuates inflammatory response by regulating macrophage polarization in rheumatoid arthritis mice | |
| US7638481B2 (en) | Treatment of spinal cord injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Free format text: PHARMEXA A/S (DK) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO DE FOLHAS 193 A 197 PUBLICADO NA RPI N.O 1979, DE 09/12/2008. ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |